Long-Term Effects of Rosiglitazone on the Progressive Decline in Renal Function in Patients With Type 2 Diabetes

Abstract Aims Very few studies have ever examined the effects of long-term (>1 year) administration of liraglutide in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Therefore, we conducted a 2-year study to prospectively examine the effects of liraglutide in those patients. Methods A total of 148 patients with T2DM were enrolled and treated with liraglutide (0.6 or 0.9 mg/day). 97 patients completed the 2-year study without protocol deviations. These patients were divided into 3 groups according to the baseline estimated glomerular filtration ratio (eGFR) (in mL/min/1.73 m2): group A, ≥60 (n=39); group B, ≥30 to <60 (n=38); and group C, <30 (n=20). The changes in blood and urine variables, and echocardiographic left ventricular mass index (LVMI) from baseline to 2 years were analyzed in each group. Primary outcomes were changes of the renal parameters of eGFR and albuminuria after the treatment of liraglutide. Results Blood glucose and systolic blood pressure decreased significantly after 24 months of liraglutide treatment in all groups compared with baseline (p<0.05). The eGFR increased significantly in group B (p<0.05), and remained unchanged in groups A and C. Albuminuria and LVMI decreased significantly in all 3 groups compared with baseline (p<0.05). Conclusions These findings suggest that 2 years of liraglutide treatment in Japanese patients with T2DM and impaired renal function was effective in terms of suppressing the deterioration of renal function, and reducing albuminuria. Long-term liraglutide treatment also improved glycemic control and blood pressure, and reduced left ventricular hypertrophy in this study.

Download Full-text

Long-term effects of moderate protein diet on renal function and low-grade inflammation in older adults with type 2 diabetes and chronic kidney disease

Nutrition ◽

10.1016/j.nut.2014.03.007 ◽

2014 ◽

Vol 30 (9) ◽

pp. 1045-1049 ◽

Cited By ~ 16

Author(s):

Mauro Giordano ◽

Tiziana Ciarambino ◽

Pietro Castellino ◽

Alessandro Cataliotti ◽

Lorenzo Malatino ◽

...

Keyword(s):

Type 2 Diabetes ◽

Older Adults ◽

Chronic Kidney Disease ◽

Renal Function ◽

Kidney Disease ◽

Low Grade ◽

Long Term Effects ◽

Low Grade Inflammation

Download Full-text

Faculty Opinions recommendation of Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717982095.793471985 ◽

2013 ◽

Author(s):

Gina LC Yosten ◽

Molly Elrick

Keyword(s):

Type 2 Diabetes ◽

Gastric Bypass ◽

Glucose Metabolism ◽

Glucose Tolerance ◽

Normal Glucose Tolerance ◽

Long Term Effects ◽

Normal Glucose

Download Full-text

Long-Term Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetes Mellitus in Morbidly Obese Subjects

Annals of Surgery ◽

10.1097/sla.0b013e318262ee6b ◽

2012 ◽

Vol 256 (6) ◽

pp. 1023-1029 ◽

Cited By ~ 167

Author(s):

Amanda Jiménez ◽

Roser Casamitjana ◽

Lílliam Flores ◽

Judith Viaplana ◽

Ricard Corcelles ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Gastric Bypass ◽

Bypass Surgery ◽

Gastric Bypass Surgery ◽

Morbidly Obese ◽

Long Term Effects ◽

Obese Subjects

Download Full-text

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis

PeerJ ◽

10.7717/peerj.3405 ◽

2017 ◽

Vol 5 ◽

pp. e3405 ◽

Cited By ~ 11

Author(s):

Lubin Xu ◽

Yang Li ◽

Jiaxin Lang ◽

Peng Xia ◽

Xinyu Zhao ◽

...

Keyword(s):

Type 2 Diabetes ◽

Renal Function ◽

Diabetic Patients ◽

Controlled Trials ◽

Cochrane Central Register ◽

Type 2 Diabetic Patients ◽

Sglt2 Inhibition ◽

Type 2 Diabetic

Aim To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes. Methods We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model. Results Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), −0.33 ml/min per 1.73 m2, 95% CI [−0.90 to 0.23]) or in patients with chronic kidney disease (CKD) (WMD −0.78 ml/min per 1.73 m2, 95% CI [−2.52 to 0.97]). SGLT2 inhibition was associated with eGFR reduction in short-term trials (WMD −0.98 ml/min per 1.73 m2, 95% CI [−1.42 to −0.54]), and with eGFR preservation in long-term trials (WMD 2.01 ml/min per 1.73 m2, 95% CI [0.86 to 3.16]). Urine ACR reduction after SGLT2 inhibition was not statistically significant in type 2 diabetic patients in general (WMD −7.24 mg/g, 95% CI [−15.54 to 1.06]), but was significant in patients with CKD (WMD −107.35 mg/g, 95% CI [−192.53 to −22.18]). Conclusions SGLT2 inhibition was not associated with significant changes in eGFR in patients with type 2 diabetes, likely resulting from a mixture of an initial reduction of eGFR and long-term renal function preservation. SGLT2 inhibition was associated with statistically significant albuminuria reduction in type 2 diabetic patients with CKD.

Download Full-text

Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes

Journal of Hypertension ◽

10.1097/hjh.0000000000002543 ◽

2020 ◽

Vol 38 (11) ◽

pp. 2279-2286

Author(s):

Francesca Viazzi ◽

Elisa Russo ◽

Antonio Mirijello ◽

Paola Fioretto ◽

Carlo Giorda ◽

...

Keyword(s):

Blood Pressure ◽

Type 2 Diabetes ◽

Renal Function ◽

Blood Pressure Variability

Download Full-text

Metformin regulates TRPM6, a potential explanation for magnesium imbalance in type 2 diabetes patients

Canadian Journal of Physiology and Pharmacology ◽

10.1139/cjpp-2019-0570 ◽

2020 ◽

Vol 98 (6) ◽

pp. 400-411 ◽

Cited By ~ 2

Author(s):

Hacene Bouras ◽

Sara R. Roig ◽

Steef Kurstjens ◽

Cees J.J. Tack ◽

Mohamed Kebieche ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cell Surface ◽

Fine Tuning ◽

Metformin Treatment ◽

Long Term Effects ◽

Short Term ◽

Metformin Therapy ◽

Diabetes Patients

Metformin therapy is associated with lower serum magnesium (Mg2+) levels in type 2 diabetes patients. The TRPM6 channel determines the fine-tuning of Mg2+ (re)absorption in intestine and kidney. Therefore, we aimed to investigate the short- and long-term effects of metformin on TRPM6. Patch clamp recordings and biotinylation assays were performed upon 1 h of incubation with metformin in TRPM6-transfected HEK293 cells. Additionally, 24 h of treatment of mDCT15 kidney and hCaco-2 colon cells with metformin was applied to measure the effects on endogenous TRPM6 expression by quantitative real-time PCR. To assess Mg2+ absorption, 25Mg2+ uptake measurements were performed using inductively coupled plasma mass spectrometry. Short-term effects of metformin significantly increased TRPM6 activity and its cell surface trafficking. In contrast, long-term effects significantly decreased TRPM6 mRNA expression and 25Mg2+ uptake. Metformin lowered TRPM6 mRNA levels independently of insulin- and AMPK-mediated pathways. Moreover, in type 2 diabetes patients, metformin therapy was associated with lower plasma Mg2+ concentrations and fractional excretion of Mg2+. Thereby, short-term metformin treatment increases TRPM6 activity explained by enhanced cell surface expression. Conversely, long-term metformin treatment results in downregulation of TRPM6 gene expression in intestine and kidney cells. This long-term effect translated in an inverse correlation between metformin and plasma Mg2+ concentration in type 2 diabetes patients.

Download Full-text